HRP20050735A2 - Dihydropteridinones, method for the production and use thereof in the form of drugs - Google Patents

Dihydropteridinones, method for the production and use thereof in the form of drugs

Info

Publication number
HRP20050735A2
HRP20050735A2 HR20050735A HRP20050735A HRP20050735A2 HR P20050735 A2 HRP20050735 A2 HR P20050735A2 HR 20050735 A HR20050735 A HR 20050735A HR P20050735 A HRP20050735 A HR P20050735A HR P20050735 A2 HRP20050735 A2 HR P20050735A2
Authority
HR
Croatia
Prior art keywords
dihydropteridinones
drugs
production
therefrom
groups
Prior art date
Application number
HR20050735A
Other languages
Croatian (hr)
Inventor
Hoffmann Matthias
Grauert Matthias
Brandl Trixi
Breitfelder Steffen
Eickmeier Christian
Steegmaier Martin
Schnapp Gisela
Baum Anke
Jens
Solca Flavio
Colbatzky Florian
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of HRP20050735A2 publication Critical patent/HRP20050735A2/en
Publication of HRP20050735B1 publication Critical patent/HRP20050735B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Izum se odnosi na nove dihidropteridinone s općomformulom (I)pri čemu skupine L i R1- R5 imaju značenje dano u patentnim zahtjevima i specifikaciji,izomere otud, proces za pripravu tih dihidropteridinona i upotrebu otud kao farmaceutskih pripravaka.The invention relates to novel dihydropteridinones of general formula (I) wherein the groups L and R 1 -R 5 have the meaning given in the claims and specification, the isomers therefrom, the process for the preparation of these dihydropteridinones and their use therefrom as pharmaceutical compositions.

HRP20050735AA 2003-02-26 2005-08-25 Dihydropteridinones, method for the production and use thereof in the form of drugs HRP20050735B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/001935 WO2004076454A1 (en) 2003-02-26 2003-02-26 Dihydropteridinones, method for the production and use thereof in the form of drugs

Publications (2)

Publication Number Publication Date
HRP20050735A2 true HRP20050735A2 (en) 2006-07-31
HRP20050735B1 HRP20050735B1 (en) 2013-08-31

Family

ID=32921552

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050735AA HRP20050735B1 (en) 2003-02-26 2005-08-25 Dihydropteridinones, method for the production and use thereof in the form of drugs

Country Status (27)

Country Link
EP (1) EP1599478B1 (en)
JP (1) JP3876265B2 (en)
KR (1) KR100983462B1 (en)
CN (2) CN101200457A (en)
AT (1) ATE361924T1 (en)
AU (1) AU2003215591B2 (en)
BR (1) BR0318145A (en)
CA (1) CA2517020C (en)
CY (1) CY1106752T1 (en)
DE (1) DE50307267D1 (en)
DK (1) DK1599478T3 (en)
EA (1) EA008778B1 (en)
ES (1) ES2287583T3 (en)
HK (1) HK1089444A1 (en)
HR (1) HRP20050735B1 (en)
IL (1) IL170419A (en)
ME (1) ME00376B (en)
MX (1) MXPA05009068A (en)
NO (1) NO332538B1 (en)
NZ (1) NZ542498A (en)
PL (1) PL226417B1 (en)
PT (1) PT1599478E (en)
RS (1) RS52386B (en)
SI (1) SI1599478T1 (en)
TW (1) TWI313600B (en)
UA (1) UA80743C2 (en)
WO (1) WO2004076454A1 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1632493A1 (en) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridine derivatives, methods for their preparation and their use as drugs
JP2008510771A (en) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone, process for its preparation and its use as a pharmaceutical agent
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2629249C (en) 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
AU2012256410B2 (en) * 2006-02-08 2016-04-28 Boehringer Ingelheim International Gmbh Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
EP2029599A1 (en) * 2006-05-19 2009-03-04 Astra Zeneca AB Dihydropteridine compounds as anti proliferative agents
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008051493A2 (en) 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
MX2009006345A (en) 2006-12-14 2009-06-23 Vertex Pharma Compounds useful as protein kinase inhibitors.
MX2009006700A (en) 2006-12-21 2009-06-30 Vertex Pharma 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors.
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
EP3098223A1 (en) * 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
JP5410432B2 (en) 2007-09-28 2014-02-05 サイクラセル リミテッド Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009071480A2 (en) * 2007-12-04 2009-06-11 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
MX2011000021A (en) * 2008-06-23 2011-02-24 Vertex Pharma Protein kinase inhibitors.
DK2331092T3 (en) 2008-08-21 2014-05-19 Univ Johns Hopkins Methods and compositions for administering 3-halopyruvate and associated compounds for the treatment of cancer
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PL2364314T3 (en) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulators of toll-like receptors
JP5908728B2 (en) * 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Pyrimido-diazepinone kinase skeletal compounds and methods of treating diseases
GEP20156325B (en) 2009-06-17 2015-07-10 Vertex Pharma Inhibitors of influenza viruses replication
PL2477987T3 (en) 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102020643A (en) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 dihydropteridine ketone derivative, and preparation method and medicinal application thereof
WO2011038185A2 (en) 2009-09-25 2011-03-31 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
KR20120094920A (en) 2009-09-25 2012-08-27 버텍스 파마슈티칼스 인코포레이티드 Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011079118A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc Pteridinones as inhibitors of polo-like kinase
WO2011101369A1 (en) 2010-02-17 2011-08-25 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
CN102190669A (en) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 Dihydro pteridinone derivatives, preparation method thereof and application thereof in medicines
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8546566B2 (en) * 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
WO2012083117A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
CN103998036B (en) 2011-10-19 2017-05-31 西格诺药品有限公司 Using TOR kinase inhibitor for treating cancers
JP2015501793A (en) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー Dihydropteridinones
PE20141696A1 (en) 2011-12-02 2014-11-08 Signal Pharm Llc PHARMACEUTICAL COMPOSITIONS OF 7- (6- (2-HYDROXYPROPAN-2-IL) PYRIDIN-3-IL) -1 - ((TRANS) -4-METOXICICLOHEXIL) -3,4-DIHIDROPIRAZINO [2,3-B] PIRAZIN- 2 (1H) -ONA, A SOLID FORM OF THE SAME AND METHODS OF ITS USE
JP5807750B2 (en) * 2012-01-05 2015-11-10 トヨタ自動車株式会社 Fastening device and fastening method
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
JP6114317B2 (en) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Method of treating non-small cell lung cancer using combination therapy of TOR kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US20140154304A1 (en) 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
NZ630467A (en) 2013-01-16 2017-02-24 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JP6052527B2 (en) * 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone I
EP2958918B1 (en) * 2013-02-21 2016-12-07 Boehringer Ingelheim International GmbH Dihydropteridinones ii
JP2016516815A (en) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 1-ethyl-7- (2-methyl-6- (1H-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 Pharmaceutical formulations, processes, solid forms and methods of use for (1H) -one
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
BR112015026297B1 (en) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc USE OF A TOR KINASE INHIBITOR AND 5-SUBSTITUTED QUINAZOLINONE, PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM, AND KIT
BR112015026292B1 (en) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc USE OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOLE-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN -2(1H)- ONA AND IN VITRO METHODS
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
TW201521725A (en) 2013-04-17 2015-06-16 Signal Pharm Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
CN109503591B (en) 2013-05-29 2022-03-01 西格诺药品有限公司 Pharmaceutical compositions of dihydropyrazinopyrazine compounds, solid forms thereof and their use
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP6618901B2 (en) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Methods for preparing inhibitors of influenza virus replication
PL3068776T3 (en) 2013-11-13 2019-10-31 Vertex Pharma Inhibitors of influenza viruses replication
EP3099171A4 (en) * 2014-01-31 2017-08-09 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017514806A (en) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Methods of treating cancer using TOR kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
CN104003989B (en) * 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 Fu Lasai for and the preparation method of intermediate
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US9623028B2 (en) 2014-07-14 2017-04-18 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
KR20170032474A (en) * 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. Dihydropteridinone derivatives and uses thereof
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EP3194401B1 (en) 2014-09-16 2020-10-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
KR102306860B1 (en) 2014-09-16 2021-09-30 길리애드 사이언시즈, 인코포레이티드 Methods of preparing toll-like receptor modulators
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
BR112018004618A2 (en) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. cyan thienotriazoldiazepines and uses thereof
PE20181086A1 (en) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc ACETAMIDE HAVE THRIZOLODIAZEPINES AND USES OF THE SAME
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
BR112018009798A8 (en) 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc bivalent bromodomain inhibitors and their uses
CN105801582A (en) * 2016-04-12 2016-07-27 合肥工业大学 Novel dihydro pteridinone derivative, preparing method thereof and application to medicine
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
CN106977584B (en) * 2017-04-19 2019-12-06 吉林大学 Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof
MX2019015731A (en) 2017-06-22 2020-08-03 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection.
CA3080941A1 (en) 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Nek inhibitors and methods of use
JP2021511352A (en) 2018-01-25 2021-05-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combined treatment with acute myeloid leukemia
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110343109B (en) * 2019-08-21 2021-11-23 郑州大学 Dihydropyridone-sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof
WO2023196943A1 (en) 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169778B2 (en) * 1999-09-15 2007-01-30 Warner-Lambert Company Pteridinones as kinase inhibitors
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
UA76512C2 (en) * 2001-09-04 2006-08-15 Boehringer Ingelheim Pharma Dihydropteridinones, a method for producing thereof and use thereof as medicament

Also Published As

Publication number Publication date
HK1089444A1 (en) 2006-12-01
ME00376B (en) 2011-10-10
CN1745081A (en) 2006-03-08
ATE361924T1 (en) 2007-06-15
IL170419A (en) 2013-11-28
CN101200457A (en) 2008-06-18
MEP58808A (en) 2011-05-10
RS20050648A (en) 2007-11-15
UA80743C2 (en) 2007-10-25
AU2003215591A1 (en) 2004-09-17
MXPA05009068A (en) 2005-10-19
NZ542498A (en) 2009-01-31
BR0318145A (en) 2006-02-21
TWI313600B (en) 2009-08-21
DK1599478T3 (en) 2007-09-17
KR20050113198A (en) 2005-12-01
NO332538B1 (en) 2012-10-15
EP1599478A1 (en) 2005-11-30
WO2004076454A1 (en) 2004-09-10
EA008778B1 (en) 2007-08-31
EA200501222A1 (en) 2006-04-28
JP2006514667A (en) 2006-05-11
DE50307267D1 (en) 2007-06-21
AU2003215591B2 (en) 2010-06-17
PL378168A1 (en) 2006-03-06
CY1106752T1 (en) 2012-05-23
HRP20050735B1 (en) 2013-08-31
CN100537570C (en) 2009-09-09
KR100983462B1 (en) 2010-09-27
JP3876265B2 (en) 2007-01-31
SI1599478T1 (en) 2007-10-31
PL226417B1 (en) 2017-07-31
RS52386B (en) 2013-02-28
NO20054414L (en) 2005-09-23
PT1599478E (en) 2007-05-31
CA2517020C (en) 2012-06-26
CA2517020A1 (en) 2004-09-10
ES2287583T3 (en) 2007-12-16
TW200417369A (en) 2004-09-16
EP1599478B1 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
HRP20050735A2 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
GB0313612D0 (en) Organic compounds
SE0301010D0 (en) Novel compounds
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
SE0301009D0 (en) Novel compounds
HRP20070076A2 (en) Pyrimidine derivatives
NO20074592L (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
HK1090559A1 (en) Immunosuppressant compounds and compositions
TW200505442A (en) Immunosuppressant compounds and compositions
TW200505428A (en) Immunosuppressant compounds and compositions
HRP20050531B1 (en) Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
ATE367809T1 (en) CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTIVE AGENTS
MY142029A (en) Phenoxyacetic acid derivatives
MY147262A (en) 1-aza-bicyclo[3.3.1]nonanes
TNSN07360A1 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
MEP43408A (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
TW200626593A (en) Novel compounds
MX2009010505A (en) Pyridine and pyrimidine derivatives as mglur2 antagonists.
DE60232158D1 (en) LIPOPEPTIDE STEREOISOMERS, METHOD FOR THEIR PRODUCTION AND USEFUL INTERMEDIATE PRODUCTS
CL2003002565A1 (en) COMPOUNDS DERIVED FROM 3H-QUINAZOLIN-4-ONA, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND USE IN THE TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MAO-B INHIBITORS, SUCH AS THE DISEASE OF ALZHEIMER AND DEMENCIER
SE0300091D0 (en) Novel compounds
MX2009010729A (en) Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives.
MY139549A (en) Dihydropteridinones, method for the production and use thereof in the form of drugs

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170207

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20180226